๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials Shanghai
Clinical trial register · China

Clinical Trials in Shanghai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 454 Fuzhou 9 Hangzhou 8 Zhengzhou 7 Yangzhou 5
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai454 Fuzhou9 Hangzhou8 Zhengzhou7 Yangzhou5
All 52 locations
Target enrolment
to

Trials with a site in Shanghai

454 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Iparomlimab and Tuvonralimab Combined With GC in Advanced ICC
NCT07152769Advanced Intrahepatic Cholangiocarcinoma
Fudan University
Phase 2
104
Shanghai
2025-10-15
Recruiting
The Fever Clinic Acute Respiratory Cohort
NCT07278700Acute Respiratory Infections, Febrile Illnesses, Community-acquired Pneumonia, Viral Respiratory Tract Infections
Fudan University
Observational
1,000
Shanghai
2025-10-10
Recruiting
Using ctDNA Methylation to Monitor Metastatic Colorectal Cancer Treatment (PROMET)
NCT07283575Metastatic Colorectal Cancer ctDNA Surveillance
Fudan University
Observational
497
Shanghai
2025-10-10
By invitation
The Effects of a Nurse-led TGA-based Pre-rehabilitation Planning on Perioperative Outcomes in Patients With Liver Cancer: Study and Protocol
NCT07537205Liver Cancer
Fudan University
Not applicable
92
Shanghai
2025-10-08
Not yet open
Development and Validation of an Artificial Intelligence-assisted System for Bowel Cleanliness Assessment Based on Withdrawal Distance Weighting
NCT07150130Colorectal Adenoma
Fudan University
Observational
700
Shanghai
2025-10-01
Not yet open
Vebreltinib for Neoadjuvant in METex 14 Skipping Mutant Stage IIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)
NCT07156604NSCLC, Neoadjuvant Therapy
Fudan University
Phase 2
30
Shanghai
2025-09-30
Recruiting
SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment
NCT07182721HER2-positive, Unresectable, Locally Advanced or Metastatic Breast Cancer, SKB264, Inetetamab
Fudan University
Phase 2
48
Shanghai
2025-09-30
Recruiting
Population Pharmacokinetics of Remifentanil in Low-Weight Critically Ill Patients
NCT07301970Critical Illness, Pain
Fudan University
Observational
45
Shanghai
2025-09-22
Not yet open
Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer
NCT07117877Platinum Resistant Ovarian Cancer, Platinum Refractory Epithelial Ovarian Cancer, Ovarian Cancer (OvCa)
Fudan University
Phase 2
33
Shanghai
2025-09-15
Not yet open
Impact of Neuropathy on the Risk of Semaglutide-Induced Gastric Retention
NCT07156591Gastric Retention
Fudan University
Observational
460
Shanghai
2025-09-15
Not yet open
Impact of a One-Week Discontinuation of Semaglutide on Gastric Retention and Endoscopic Mucosal Visibility Scores
NCT07152756Gastric Retention
Fudan University
Observational
418
Shanghai
2025-09-15
Not yet open
Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study
NCT07179939HER2-positive Breast Cancer
Fudan University
Phase 2
288
Shanghai
2025-09-10
Recruiting
Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer
NCT07194005Gastric Cancer
Fudan University
Phase 2
30
Shanghai
2025-09-04
Not yet open
Cryoablation Combined With SHR-1701 Plus Famitinib in Patients With Advanced Intrahepatic Cholangiocarcinoma.
NCT07147088Advanced Intrahepatic Cholangiocarcinoma
Fudan University
Phase 2
36
Shanghai
2025-09-01
Recruiting
The Efficacy and Safety of Metformin Intervention in Elderly Overweight or Obesity With Mild Cognitive Impairment
NCT07395960Mild Cognitive Impairment, Overweight or Obesity, Elderly
Fudan University
Phase 1/2
54
Shanghai
2025-09-01
Recruiting
Multicentric Database for Solid Pseudopapillary Neoplasm of the Pancreas
NCT07183280Solid Pseudopapillary Neoplasm of the Pancreas
Fudan University
Observational
2,000
Shanghai
2025-09-01
Recruiting
Individualized Neck Cervical Irradiation Prophylaxis Trial of NPC
NCT07303023Nasopharyngeal Carcinoma (NPC)
Fudan University
Phase 3
462
Shanghai, Hangzhou, Chengdu, Chongqing
2025-09-01
Recruiting
Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment
NCT07147101Advanced Hepatocellular Carcinoma (HCC)
Fudan University
Observational
150
Shanghai
2025-09-01
Recruiting
Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G/GEJ Adenocarcinoma
NCT07389876Gastric Cancer, Second-line Treatment
Fudan University
Observational
250
Shanghai
2025-09-01
Not yet open
De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority Trial
NCT07153757Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Fudan University
Phase 3
2,934
Shanghai
2025-09-01
Not yet open
Yueju Pill Combined With Standard Therapy In Advanced Biliary Tract Cancer
NCT07169916Biliary Tract Cancer (BTC)
Fudan University
Not applicable
210
Shanghai
2025-09-01
By invitation
Immediate Autologous Tissue Breast Reconstruction and Radiotherapy Strategy After Breast Cancer Surgery
NCT07798466Breast Cancer, Breast Reconstruction, Radiotherapy
Fudan University
Observational
128
Shanghai
2025-09-01
Not yet open
Randomized Controlled Clinical Study on the Reduction of Tumor Marker Levels in Breast Cancer Patients by Huaier Granules
NCT05871437Breast Cancer
Fudan University
Phase 4
232
Shanghai
2025-09
Not yet open
T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis
NCT07150208Breast Cancer With Brain Metastasis, HER2-low Expressing Breast Cancer
Fudan University
Phase 2
140
Shanghai
2025-09
Recruiting
Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC)
NCT07150949Locally Advanced Rectal Cancer, Neoadjuvant Therapy
Fudan University
Phase 2
138
Shanghai
2025-08-28
Recruiting
Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma
NCT07070700Intrahepatic Cholangiocarcinoma (Icc)
Fudan University
Phase 2
56
Shanghai
2025-08-20
Recruiting
HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)
NCT07105748Mixed Hepatocellular-cholangiocarcinoma
Fudan University
Phase 2
45
Shanghai
2025-08-15
Recruiting
TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma: Study on Efficacy and Immune Microenvironment
NCT07100405Hepatocellular Carcinoma
Fudan University
Observational
50
Shanghai
2025-08-15
Recruiting
Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab
NCT07100392Hepatocellular Carcinoma (HCC)
Fudan University
Phase 2
141
Shanghai
2025-08-14
Recruiting
Zhongshan Ketogenic Diet Study 1
NCT07117903Platelet Function and Thrombus Formation
Fudan University
Not applicable
80
Shanghai
2025-08-10
Not yet open
Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer
NCT07025850Colorectal Carcinoma
Fudan University
Phase 1/2
20
Anyang, Shanghai
2025-08-01
Recruiting
A Study of Disitamab Vedotin + Bicalutamide in HER2/AR-Positive Scrotal Paget's Disease
NCT07117851Extramammary Paget Disease, Scrotum Disease
Fudan University
Phase 2
20
Shanghai
2025-08-01
Recruiting
Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer
NCT07154316Colorectal Cancer
Fudan University
Phase 2
138
Fuzhou, Anyang, Jinan, Kunming, Shanghai
2025-08-01
Not yet open
Transparent Cap-Assisted Colonoscopy Combined With Computer-Aided Detection in Improving the Detection Rate of Colorectal Adenomas
NCT07097350Colorectal Adenoma
Fudan University
Not applicable
524
Shanghai
2025-08-01
Active, closed
AI-LLM Communication Aid in Prostate Cancer Care (AI-CAP๏ผ‰
NCT07082049Prostate Cancer
Fudan University
Not applicable
160
Shanghai
2025-07-27
Recruiting
Incidence of 106TBL Lymph Node Metastasis
NCT07165210Esophageal Cancer
Fudan University
Observational
1,852
Shanghai
2025-07-21
Recruiting
Incidence of 107 Lymph Node Metastasis
NCT07165184Esophageal Cancer
Fudan University
Observational
1,100
Shanghai
2025-07-21
Recruiting
Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab
NCT07047586Hepatocellular Carcinoma (HCC)
Fudan University
Phase 2
146
Shanghai
2025-07-02
Not yet open
Rimegepant Combined With PD-1 in Liver Metastasis Colorectal Cancer Patients
NCT06999252Colon Cancer
Fudan University
Phase 2
20
Shanghai
2025-07-01
Not yet open
Phase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian Cancer
NCT06973421Platinum Resistant Ovarian Cancer
Fudan University
Phase 2
35
Shanghai
2025-07-01
Not yet open
Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer
NCT07041437Advanced Breast Cancer
Fudan University
Phase 2
48
Shanghai
2025-06-30
Recruiting
CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)
NCT07019363Breast Cancer, Adjuvant Therapy
Fudan University
Phase 3
1,903
Shanghai
2025-06-15
Recruiting
A Phase II Observational Clinical Study on the Relationship Between Cerebrospinal Fluid Drug Concentration and Efficacy of Trastuzumab Deruxtecan in Central Nervous System Metastatic Breast Cancer
NCT07653893Central Nervous System (CNS) Metastases, Breast Cancer
Fudan University
Observational
60
Shanghai
2025-06-11
Recruiting
Omega-3 Fatty Acids With PD-1 Inhibitors in Advanced Esophageal Cancer
NCT07272382Esophageal Neoplasms
Fudan University
Not applicable
142
Shanghai
2025-06-05
Not yet open
Patient Education Strategy for Breast Cancer Patients During Perioperative Hospitalization Stage
NCT06965556Breast Carcinoma, Patient Education, Perioperative Care, Psychological Intervention
Fudan University
Not applicable
1,138
Shanghai
2025-06-01
Recruiting
Phase โ…ก Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC
NCT07003022Colo-rectal Cancer, MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
Fudan University
Phase 2
40
Shanghai
2025-06-01
Not yet open
Preservation Vs. Dissection of No. 253 Lymph Nodes of Robotic Resection for Mid/Low Rectal Cancer
NCT06956976Rectal Cancer
Fudan University
Not applicable
1,596
Shanghai
2025-06-01
Not yet open
UEMR Versus HSP in the Treatment of Pedunculated Colorectal Polyps Less Than 10mm in Size
NCT06996522Pedunculated Colorectal Polyp
Fudan University
Not applicable
338
Shanghai
2025-06-01
Recruiting
HPV Genotype Attribution and Disease Burden of Anal Cancer in China
NCT06670495Anal Cancer
Fudan University
Observational
300
Shanghai
2025-06-01
Not yet open
The Effect of Cap-assisted Water Exchange Colonoscopy on Straight Passage of the Colonoscope Through the Sigmoid Colon, Without Loop Formation
NCT06992856Colonoscope Passage
Fudan University
Not applicable
531
Shanghai
2025-06-01
Recruiting
Granzyme B-PET: Predicting Immunotherapy Efficacy in TNBC
NCT07705438Triple Negative Breast Cancer, Immune Checkpoint Inhibitor, Granzyme B PET/CT
Fudan University
Observational
30
Shanghai
2025-05-28
Recruiting
Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer
NCT06970353Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation, Advanced PDTC or ATC With NRAS Mutation
Fudan University
Phase 2
40
Shanghai
2025-05-27
Recruiting
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL
NCT06966154Natural Killer/T-cell Lymphoma, Relapsed or Refractory Lymphoma Including ENKL
Fudan University
Phase 1/2
68
Shanghai
2025-05-26
Recruiting
GemCis Plus PD-1/PD-L1 Inhibitor in Advanced Biliary Tract Cancer: Efficacy and Immune Microenvironment ๏ผˆBTC-IM-1๏ผ‰
NCT06988592Advanced Biliary Tract Cancer
Fudan University
Observational
100
Shanghai
2025-05-23
Recruiting
A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell Carcinoma
NCT07105592Head and Neck Squamous Cell Carcinoma
Fudan University
Phase 1/2
68
Shanghai
2025-05-13
Recruiting
Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET
NCT07070648Diffuse Large B-Cell Lymphoma, DLBCL
Fudan University
Observational
300
Shanghai
2025-05-09
Not yet open
Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)
NCT06919848Biliary Tract Cancer (BTC)
Fudan University
Phase 2
74
Shanghai
2025-05-01
Not yet open
Active Surveillance for Limited GGNs
NCT06394037Lung Ground-glass Opacities, Active Surveillance
Fudan University
Observational
387
Shanghai
2025-05-01
Not yet open
Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Carcinoma
NCT06957938Laryngeal Carcinoma, Hypopharyngeal Carcinoma
Fudan University
Phase 3
168
Shanghai
2025-04-28
Recruiting
MRG003 and Pucotenlimab to Treat Locally Advanced or Metastatic ATC/PDTC
NCT07235566Thyroid Cancer
Fudan University
Phase 2
60
Shanghai
2025-04-21
Recruiting
RGL-305+ Lymphoma + Exploratory Clinical Study
NCT07006012Lymphoma Patients With Complete Response (CR) or Partial Response (PR) After Standard Treatment Had a Positive Minimal Residual Lesion (MRD)
Fudan University
Not applicable
12
Shanghai
2025-04-21
Recruiting
Effect of Surgical Margin Width on Recurrence and Survival in Patients With Hepatic Oligometastasis of Colorectal Cancer
NCT06934018Oncology, Tumor Recurrence and Metastasis
Fudan University
Not applicable
140
Shanghai
2025-04-21
Recruiting
TQB2450 Plus Progestin for Fertility-sparing Treatment in MMRd EC
NCT06914297Endometrial Cancer
Fudan University
Phase 2
10
Shanghai
2025-04-21
By invitation
Breast Cancer PET/CT Imaging With 68Ga-pAKTi
NCT06943313Breast Cancers, PIK3CA Mutation-Related Tumors, PI3K Pathway Activated Tumors, PET / CT
Fudan University
Observational
20
Shanghai
2025-04-21
Recruiting
Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases
NCT07134153Breast Cancer
Fudan University
Phase 1/2
139
Shanghai
2025-04-18
Active, closed
Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
NCT06914687Gastric Adenocarcinoma, Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma, Peritoneal Metastasis
Fudan University
Phase 2
30
Shanghai
2025-04-15
Recruiting
Neoadjuvant SNF Precision Therapy Phase III
NCT06913777Neoadjuvant Therapy
Fudan University
Phase 3
404
Shanghai
2025-04-08
Recruiting
Molecular Subtyping of Breast Cancer-derived Small Extracellular Vesicles (sEVs) to Predict Therapeutic Efficacy
NCT07574749Breast Cancer
Fudan University
Observational
1,500
Shanghai
2025-04-07
Not yet open
HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer
NCT06849492Advanced Triple Negative Breast Cancer
Fudan University
Phase 2
120
Shanghai
2025-04-01
Recruiting
A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer
NCT07562490ctDNA, Chemotherapy, Colorectal Cancer
Fudan University
Phase 2
100
Shanghai
2025-04-01
Recruiting
Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas
NCT06914674Pancreatic Neoplasms
Fudan University
Phase 2
30
Shanghai
2025-03-20
Recruiting
HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)
NCT06860490Hepatocellular Carcinoma (HCC)
Fudan University
Phase 2
164
Shanghai
2025-03-18
Recruiting
Cryoablation Combined With Lenvatinib Plus Tislelizumab Compared With FOLFOX in Patients With Advanced Intrahepatic Cholangiocarcinoma (CASTLE-ZS-01)
NCT06860477Intrahepatic Cholangiocellular Carcinoma
Fudan University
Phase 2
92
Shanghai
2025-03-18
Recruiting
Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer
NCT06928584Locally Recurrent Rectal Cancer
Fudan University
Phase 2
221
Shanghai
2025-03-10
Recruiting
Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)
NCT07183865Locally Recurrent Rectal Cancer
Fudan University
Phase 2
44
Shanghai
2025-03-09
Recruiting
Corticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin Reactions
NCT07362914Breast Cancer
Fudan University
Phase 3
182
Shanghai
2025-03-07
Recruiting
Perioperative Immunotherapy for Resectable Limited-Stage SCLC
NCT07109401Perioperative Immunotherapy, Limited Stage Lung Small Cell Carcinoma, Resectable Small Cell Lung Cancer
Fudan University
Phase 2
37
Shanghai
2025-03-01
Recruiting
Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer
NCT06521866Advanced Colorectal Carcinoma, Immunotherapy
Fudan University
Phase 2
208
Fuzhou, Xiamen, Lanzhou, Zhengzhou, Huaian, Jinan, Taian, Shanghai
2025-03-01
Not yet open
Predicting Gastric Neoplasia in Patients with High-risk Endoscopic Features
NCT06853509Gastric Neoplasia
Fudan University
Observational
2,700
Shanghai
2025-03-01
Recruiting
A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer
NCT06856200Advanced HR - Positive, HER2 - Negative Breast Cancer, Resistant to (Neo)Adjuvant Endocrine Therapy
Fudan University
Not applicable
36
Shanghai
2025-02-28
Recruiting
Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer
NCT06856187Metastatic Colorectal Cancer (CRC)
Fudan University
Phase 2
119
Shanghai
2025-02-28
Recruiting
Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer
NCT06763029Colorectal Cancer Metastatic
Fudan University
Phase 2
36
Shanghai
2025-02-26
Recruiting
IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)
NCT06849986Soft Tissue Sarcomas, Angiosarcoma, Fibrosarcoma, Leiomyosarcoma
Fudan University
Phase 2
45
Shanghai
2025-02-25
Recruiting
POLA-R-CHP in the First-line Treatment of Transformed DLBCL
NCT06743945Transformed Lymphoma
Fudan University
Phase 2
20
Shanghai
2025-02-17
Not yet open
Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Triple-negative Breast Cancer
NCT06798506TNBC - Triple-Negative Breast Cancer
Fudan University
Observational
300
Shanghai
2025-02-15
Not yet open
Heterogeneity of 68Ga-FAPI Uptake As Imaging Biomarker in T-DXd Treatment for Brain Metastasis of HER2 Positive Breast Cancer
NCT06797622Breast Cancer, Metastatic Breast Cancer
Fudan University
Phase 2
50
Shanghai
2025-02-15
Recruiting
Reverse HER2-negative Immune Resistant Breast Cancer
NCT06731140HER2 Negative Breast Cancer
Fudan University
Phase 2
10
Shanghai
2025-02-12
Recruiting
Pyrotinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docetaxel in Advanced HER2-Positive Breast Cancer
NCT07615751Breast Cancer
Fudan University
Phase 3
502
Shanghai
2025-02-12
Not yet open
Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT06814067Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC
Fudan University
Phase 2
80
Shanghai
2025-02-10
Recruiting
Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations
NCT07117890Non Small Cell Lung Cancer
Fudan University
Phase 2
34
Shanghai
2025-02-07
Recruiting
CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC
NCT06964568Esophageal Carcinoma, Radiotherapy, Immunotherapy
Fudan University
Phase 3
452
Shanghai
2025-02-01
Recruiting
Epidemiology and Prognostic Analysis of Chinese Cancer Patients With Cancer-related Fatigue
NCT07656324Cancer
Fudan University
Observational
1,000,000
Shanghai
2025-01-17
Rows per page Showing 101–200 of 454
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/shanghai?page=2

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 454 of those studies with a site in Shanghai that also match the filters currently applied.

How many clinical trials are recruiting in Shanghai?

295 of the 454 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 104 have not yet opened recruitment, 49 are active but closed to new participants, and 6 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.